Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of carcinoid syndrome: a systematic review and meta-analysis
Johannes Hofland, Aura D. Herrera‐Martínez, Wouter T. Zandee, et al.
Endocrine Related Cancer (2019) Vol. 26, Iss. 3, pp. R145-R156
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
Anna Kathrin Stueven, Antonin Kayser, Christoph Wetz, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 12, pp. 3049-3049
Open Access | Times Cited: 171
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Johannes Hofland, Gregory Kaltsas, Wouter W. de Herder
Endocrine Reviews (2019) Vol. 41, Iss. 2, pp. 371-403
Open Access | Times Cited: 162
Multiple Endocrine Neoplasia Type 1: Latest Insights
Maria Luisa Brandi, Sunita Agarwal, Nancy D. Perrier, et al.
Endocrine Reviews (2020) Vol. 42, Iss. 2, pp. 133-170
Open Access | Times Cited: 146
European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
Simona Grozinsky‐Glasberg, Joseph Davar, Johannes Hofland, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 7
Open Access | Times Cited: 100
Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome
Dominique Clement, John Ramage, Raj Srirajaskanthan
Journal of Oncology (2020) Vol. 2020, pp. 1-11
Open Access | Times Cited: 64
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
Morticia N. Becx, Noémie S. Minczeles, Tessa Brabander, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5792-5792
Open Access | Times Cited: 31
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
Wouter T. Zandee, Tessa Brabander, Anela Blažević, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 9, pp. e3665-e3672
Open Access | Times Cited: 41
Peptide Receptor Radionuclide Therapy
Johannes Hofland, Tessa Brabander, Frederik A. Verburg, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 12, pp. 3199-3208
Open Access | Times Cited: 26
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
Federico Gatto, Federica Barbieri, Marica Arvigo, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 16, pp. 3940-3940
Open Access | Times Cited: 36
Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal
María Isabel del Olmo-García, M.A. Muros, Martín López de la Torre Casares, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2203-2203
Open Access | Times Cited: 33
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators
Merijn C F Mulders, Wouter W. de Herder, Johannes Hofland
Endocrine Reviews (2023) Vol. 45, Iss. 3, pp. 351-360
Open Access | Times Cited: 11
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants
Rosa Luo, Ajay Madan, Christine Ferrara-Cook, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review)
Maria-Evangelia Koloutsou, Maria Soura, Dimitrios Andreikos, et al.
Molecular and Clinical Oncology (2025) Vol. 22, Iss. 4, pp. 1-10
Open Access
A phase 1 study to assess the safety, tolerability and effectiveness of PV-10 (Rose Bengal Sodium) in neuroendocrine tumours metastatic to the liver
Timothy Price, Laura Depauw, Gabrielle Cehic, et al.
British Journal of Cancer (2025)
Open Access
Gastrointestinal neuroendocrine tumor syndromes (GI-NETS)
Tetsuhide Ito, Robert T. Jensen
Elsevier eBooks (2025)
Closed Access
Carcinoid syndrome
Marina Tsoli, Gregory Kaltsas
Elsevier eBooks (2025)
Closed Access
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Kimberly Perez, Jaydira Del Rivero, Erin B. Kennedy, et al.
JCO Oncology Practice (2025)
Closed Access
Therapy Sequencing in Patients With Advanced Neuroendocrine Neoplasms
Rachel P. Riechelmann, Rodrigo G. Taboada, Victor Hugo Fonseca de Jesus, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 9
Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?
Aura D. Herrera‐Martínez, Antonio C. Fuentes-Fayos, Rafael Sánchez-Sánchez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2036-2036
Open Access | Times Cited: 3
Carcinoid Syndrome: Updates and Review of Current Therapy
Kira Oleinikov, Shani Avniel-Polak, David J. Gross, et al.
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 9
Closed Access | Times Cited: 24
Endocrine therapies for breast and prostate cancers
Geneviève Chaput, Nureen Sumar
Canadian Family Physician (2022) Vol. 68, Iss. 4, pp. 271-276
Open Access | Times Cited: 13
How I treat neuroendocrine tumours
Barbara Kiesewetter, Markus Raderer
ESMO Open (2020) Vol. 5, Iss. 4, pp. e000811-e000811
Open Access | Times Cited: 19
The role of serotonin inhibition within the treatment of carcinoid syndrome
Joel George, John Ramage, Benjamin White, et al.
Endocrine Oncology (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 7
Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms
Johannes Hofland, Wouter W. de Herder
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101787-101787
Open Access | Times Cited: 7
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
Maria Passhak, Mairéad G. McNamara, Richard Hubner, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101836-101836
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top